RoverMed has developed targeted, twenty nanometer nanocapsule technology capable of reaching the most challenging disease sites and delivering cargo – intact – into the nucleus of target cells, regardless of where these cells are located in the body.
 

RoverMed’s nanocapsule technology has been proven, through years of intensive research and development, by Minnesota-based GeneSegues Therapeutics. A precision target drug delivery platform has been developed initially for solid tumor cancers of the head and neck, prostate, and colon.

RoverMed is now applying this technology toward a broader spectrum of treatment applications, in partnership with larger drug developers, in order to expand the acceptance, use and impact on a host of new, exciting applications.